ClinicalTrials.Veeva

Menu
T

The Lung Research Center, LLC | Chesterfield, MO

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Nintedanib
BI 1015550
Treprostinil
Zinpentraxin Alfa
BMS-986278
PRM-151
DWN12088
MK-7264-030
BLU-5937
Bexotegrast

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 31 total trials

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.

Enrolling
Idiopathic Pulmonary Fibrosis
Drug: BMS-986278 Placebo
Drug: BMS-986278

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.

Enrolling
Progressive Pulmonary Fibrosis
Drug: BMS-986278 Placebo
Drug: BMS-986278

This study is open to adults with a lung disease called Idiopathic Pulmonary Fibrosis (IPF). People can join the study if they are 40 years or older....

Active, not recruiting
Idiopathic Pulmonary Fibrosis
Drug: Placebo
Drug: BI 1015550

This study is open to adults with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs). People who have a form of PF-ILD other than Idiopathic...

Active, not recruiting
Lung Diseases, Interstitial
Drug: BI 1015550
Drug: Placebo

This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathi...

Enrolling
Idiopathic Pulmonary Fibrosis
Drug: DWN12088
Drug: Placebo

Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis.

Invitation-only
Idiopathic Pulmonary Fibrosis
Interstitial Lung Disease
Device: Treprostinil Ultrasonic Nebulizer
Drug: Inhaled Treprostinil

A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment o...

Enrolling
Idiopathic Pulmonary Fibrosis
Drug: PLN-74809
Drug: Placebo

Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FV...

Enrolling
Idiopathic Pulmonary Fibrosis
Interstitial Lung Disease
Drug: Inhaled Treprostinil
Drug: Placebo

Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a...

Enrolling
Progressive Pulmonary Fibrosis
Interstitial Lung Disease
Device: Treprostinil Ultrasonic Nebulizer
Drug: Placebo

The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment durat...

Enrolling
Idiopathic Pulmonary Fibrosis
Drug: TTI-101
Drug: Placebo

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, study to evaluate the efficacy, safety, and tolerability of 200 mg twic...

Active, not recruiting
Idiopathic Pulmonary Fibrosis
Drug: Placebo
Drug: BBT-877

Trial sponsors

Boehringer Ingelheim logo
United Therapeutics logo
B
Bristol-Myers Squibb (BMS) logo
Roche logo
B
B
Bridge Biotherapeutics logo
D
FibroGen logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems